The specialist for invitro diagnostics and GMPcompliant protein analysis appoints two new members for the Executive Board.
Dr. Peter Schulz-Knappe, former CSO at Proteome Sciences plc., started his new position with the beginning of the year. He will take over operational responsibility for the Business Unit Diagnostics. At the same time, Martin Blüggel, cofounder and COO, joins the board and will manage the Business Unit Protein Services.
"The new Executive Board of Protagen AG underscores the new strategic positioning in the attractive area of invitro diagnostics, and strengthens the business with our customers in pharma and biotech", says Dr. Stefan Müllner, CEO, and adds "Peter Schulz-Knappe is an international renowned expert in biomarker discovery and their targeted development into new invitro diagnostics. Therefore, he is the ideal completion of our management team."
Furthermore, Dr. Thomas Schweins, Member of the Executive Committee of Qiagen and Vice President Marketing & Strategy, completes the Supervisory Board. Dr. Schweins, a trained biochemist, is a professional expert in the global diagnostic businesses. Before joining Qiagen, he held positions in the Pharma/Health Care Unit of Boston Consulting Group, and as project manager at Hoechst AG/Aventis SA.
Background: Within the last four years, Protagen developed a strong international market position in the area of GMPcompliant protein analytical services, and belongs to the preferred partners of pharma and biotech companies. Furthermore, Protagen has developed UNIarray®, a unique technology platform for the development of novel invitro diagnostics, which allows the indication specific determination of autoantibody signatures in patient sera. Proprietary biomarker panels for differential diagnosis of Prostate Cancer and Multiple Sclerosis are currently validated in a multicentric clinical study.
Dr. Peter Schulz-Knappe, former CSO at Proteome Sciences plc., started his new position with the beginning of the year. He will take over operational responsibility for the Business Unit Diagnostics. At the same time, Martin Blüggel, cofounder and COO, joins the board and will manage the Business Unit Protein Services.
"The new Executive Board of Protagen AG underscores the new strategic positioning in the attractive area of invitro diagnostics, and strengthens the business with our customers in pharma and biotech", says Dr. Stefan Müllner, CEO, and adds "Peter Schulz-Knappe is an international renowned expert in biomarker discovery and their targeted development into new invitro diagnostics. Therefore, he is the ideal completion of our management team."
Furthermore, Dr. Thomas Schweins, Member of the Executive Committee of Qiagen and Vice President Marketing & Strategy, completes the Supervisory Board. Dr. Schweins, a trained biochemist, is a professional expert in the global diagnostic businesses. Before joining Qiagen, he held positions in the Pharma/Health Care Unit of Boston Consulting Group, and as project manager at Hoechst AG/Aventis SA.
Background: Within the last four years, Protagen developed a strong international market position in the area of GMPcompliant protein analytical services, and belongs to the preferred partners of pharma and biotech companies. Furthermore, Protagen has developed UNIarray®, a unique technology platform for the development of novel invitro diagnostics, which allows the indication specific determination of autoantibody signatures in patient sera. Proprietary biomarker panels for differential diagnosis of Prostate Cancer and Multiple Sclerosis are currently validated in a multicentric clinical study.
